HOME >> BIOLOGY >> NEWS
Cancer biologists and a cardiologist take a new look at aggressive tumors

An unusual collaboration between a University of Iowa cardiologist and cancer biologists at the Holden Comprehensive Cancer Center at the UI, the Scripps Research Institute in California and Kanagawa Cancer Center Hospital and Research Center in Japan utilized a multidisciplinary approach to learn more about how aggressive cancer cells function and how they differ from poorly aggressive cancer cells. The study, which appears in the Sept. 1 issue of Cancer Research, may also suggest potential new therapeutic targets for cancer treatment.

Previous studies have found that aggressive tumor cells express genes that are more normally associated with other cell types, including endothelial cells that line blood vessels. Also, aggressive cancer cells are able to form vascular-like, fluid-conducting networks, an ability known as vasculogenic mimicry that resembles the behavior of embryonic cells that form primitive vascular networks.

Patients' tumors that have fluid-conducting networks are much more aggressive than tumors that do not have those networks.

The present study focuses on just a few of the genes that are expressed by aggressive cancer cells but not by poorly aggressive tumor cells. These genes normally are involved in regulating anticoagulant, or blood-clotting, activity in endothelial cells. The study suggests that the expression of these genes by aggressive tumor cells provides the cells with anticoagulant capabilities that are similar to those in blood vessel cells.

"Essentially our observations indicated that the aggressive melanoma tumor cells behaved in a similar manner as do endothelial cells that form blood vessels," said Mary Hendrix, Ph.D., the Kate Daum Research Professor of Anatomy and Cell Biology and head of the department.

The finding that tumor cells have anticoagulant properties similar to endothelial cells prompted the researchers to analyze whether there was blood flow within these tumors in extravascula
'"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-335-9917
University of Iowa
4-Sep-2003


Page: 1 2

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
Cached News: